The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay
Habtom H Habte1, Anwar S Mall*1, Corena de Beer2, Zoë E Lotz1 and Delawir Kahn1

Address: 1Department of Surgery, University of Cape Town, Cape Town, South Africa and 2Discipline of Medical Virology, University of Stellenbosch and National Health Laboratory Service, Cape Town, South Africa

Email: Habtom H Habte - hhabte@uctgsh1.uct.ac.za; Anwar S Mall* - amall@uctgsh1.uct.ac.za; Corena de Beer - cdeb@sun.ac.za; Zoë E Lotz - zlotz@uctgsh1.uct.ac.za; Delawir Kahn - dkahn@uctgsh1.uct.ac.za

* Corresponding author

Abstract

Background: Despite the continuous shedding of HIV infected blood into the oral cavity and the detectable presence of the AIDS virus at a high frequency, human saliva is reported to inhibit oral transmission of HIV through kissing, dental treatment, biting, and aerosolization. The purpose of this study was to purify salivary MUC5B and MUC7 mucins from crude saliva and determine their anti-HIV-1 activities.

Methods: Following Sepharose CL-4B column chromatography and caesium chloride isopycnic density-gradient ultra-centrifugation, the purity and identity of the mucins was determined by SDS-PAGE and Western blotting analysis respectively. Subsequently an HIV-1 inhibition assay was carried out to determine the anti-HIV-1 activity of the crude saliva and purified salivary mucins by incubating them with subtype D HIV-1 prior to infection of the CD4+ CEM SS cells.

Results: Western blotting analysis confirmed that the mucin in the void volume is MUC5B and the mucin in the included volume is MUC7. The HIV inhibition assay revealed that both the crude saliva and salivary MUC5B and MUC7 mucins inhibited HIV-1 activity by 100%.

Conclusion: Although the mechanism of action is not clear the carbohydrate moieties of the salivary mucins may trap or aggregate the virus and prevent host cell entry.

Background

Several studies have shown that the human immunodeficiency virus (HIV) is not transmitted via the oral route [1]. It has also been reported that there is a continuous shedding of HIV infected blood into the oral cavity from mucosal and gingival lesions in HIV-infected patients, resulting in the detectable presence of the acquired immunodeficiency syndrome (AIDS) virus at a high frequency in the oral cavity [2-6]. However, several epidemiological studies have failed to present any conclusive evidence about oral transmission of HIV through kissing, dental treatment, biting, and aerosolization [7-14].
Extensive studies have been carried out after the initial findings of Fultz [1] that human saliva inhibited the activity of the AIDS virus [8,15,16]. These studies showed that the anti-HIV activity appeared to be highest in sub-mandibular secretions and whole saliva rather than parotid secretions [2,3,11,17-19]. Although most of these studies suggested that HIV-1 particles were aggregated by high-molecular weight components (of mucus) in both whole saliva and specifically in sub-mandibular/sublingual secretions, and which were removable by filtration through 0.45 μm pore filter [3,8,17,20,21], there has been no detailed analysis to identify the mucin components of these secretions and determine which of these components displays HIV inhibitory activity.

Thus far five secreted gel-forming (MUC2, MUC5AC, MUC5B, MUC6 MUC19), three secreted non gel-forming (MUC7, MUC8, MUC9), ten membrane bound (MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, MUC13, MUC16, MUC17, MUC20) and three unclassified mucins (MUC14, MUC15, MUC18) have been identified [22]. Human saliva is known to contain, amongst many other factors two types of mucins, namely MUC5B and MUC7 [23], and more recently MUC19 [24]. The aim of this study was to isolate and purify these mucins in the saliva and to determine their anti-HIV-1 activity individually.

In its special report on HIV and AIDS on 30 May 2006, UNAIDS stated that since its outbreak in 1981, AIDS was found to be responsible for the deaths of more than 25 million people world-wide, with 2.8 million deaths and over 4.1 million new infections in 2005 alone [25]. This report estimated that there were more than 38.6 million HIV positive people world-wide at the end of 2005, of which two-thirds of those infected lived in Sub-Saharan Africa. Of these, South Africa with 27.9% of its adult population living with HIV [26] remains one of the worst affected countries in the world [27]. This epidemic is expected to cost South Africa 17% of its GDP growth by 2010 [26]. With this in mind, the present study could make a significant contribution to the efforts being made in controlling this epidemic.

In this study we report the anti-HIV-1 activities of human crude saliva and purified salivary MUC5B and MUC7 mucins in an in vitro inhibition assay. We have shown that both crude saliva and purified MUC5B and MUC7 mucins inhibit HIV-1 activity by 100% in the range from 900 μg to 0.09 μg mucin concentration.

Materials and methods

**Ethics**

The University of Cape Town Research and Ethics Committee approved this study (ethics approval number REC REF: 283/2004).

**Materials**

The ECL™ Western Blotting Detection Kit was from Amersham Biosciences (Amersham UK). Nitrocellulose membrane and dialysis tubing were from Kimix (chemical and laboratory suppliers, SA). Polyclonal rabbit anti-MUC5B (Lum 5B-2), goat anti-MUC7, goat anti-rabbit and rabbit anti-goat horse radish peroxidise (HRPO) linked secondary antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, California). The CD4+ CEM SS cells were from AIDS Research and Reference Reagent Programme (Germantown, USA). RPMI 1640, L-Glutamine and heat-inactivated fetal bovine serum were from Gibco (Massachusetts, USA). IL-2 and p24 antigen kit were from Roche Diagnostics (Germany) and Vironostika HIV-1 Antigen kit Biomérieux (France) respectively. Sepharose CL-4B and reagent solvents such as guanidinium chloride (GuHCl), phenylmethylsulfonylfluoride (PMSF), calcium chloride (CaCl2), ethylenediaminetetra-acetic acid disodium salt (Na2-EDTA), N-ethylmaleimide (NEM), and 3-((3-cholamidopropyl)-dimethyl-ammonio)-1-propane-sulfonate (CHAPS) were from Sigma (UK). Trypan Blue Dye solution was from Merck (Germany).

**Saliva collection**

Saliva was collected from healthy symptom free ‘normal’ female and male volunteers (who declared a risk-free lifestyle) from the laboratory who abstained from eating and drinking for at least 2 h prior to collection. Whole saliva was stimulated by chewing on parafilm and collected into 6 M GuHCl containing a spectrum of protease inhibitors (10 mM EDTA, 5 mM NEM, 1 mM PMSF) and 0.1% CHAPS pH 6.5. Samples were collected on ice and then stored at -20°C.

**Sepharose CL-4B gel filtration**

Crude salivary mucus was solubilised by overnight mixing at 4°C on a revolving rotor. The insoluble debris was then separated from the soluble mucus by centrifugation at 4400 g for 10 min at 4°C.

Aliquots of the supernatant (20 ml) were chromatographed on a Sepharose CL-4B gel filtration column equilibrated and eluted with 4 M GuHCl containing 10 mM EDTA, 5 mM NEM and 0.05% CHAPS at pH 6.5 and at a flow rate of 48 ml/h at room temperature. Following PAS and protein (A280) assays, the void (V0) and included volume (V1) materials were pooled separately, dialysed against three changes of distilled water at 4°C and freeze-dried.

**Mucin preparation**

For the HIV inhibition assay, crude saliva was collected into 0.1 M Tris-HCl, 2% (w/v) EDTA and 5 mM PMSF pH 7.5 (saliva:buffer ratio 1:2). After solubilisation by overnight mixing at 4°C on a revolving rotor, the insoluble...
debris was separated by centrifugation at 10 000 g for 10 min at 4 °C. The supernatant was then dialysed over three changes of distilled water at 4 °C and freeze-dried.

The mucin that eluted in the included volume (V_i) of the column was subjected to caesium chloride isopycnic density-gradient ultra-centrifugation, twice for 48 h at a 105 000 g and 4 °C in a Beckman L45 ultra-centrifuge [28]. Briefly, V_i samples dissolved in 4 M GuHCl containing a cocktail of proteolytic inhibitors (as described above) were adjusted to a density of 1.39 to 1.40 g/ml with caesium chloride prior to centrifugation. Mucin rich fractions were pooled, dialysed against three changes of distilled water at 4 °C and freeze-dried.

**SDS-PAGE**

SDS-PAGE was carried out according to the method of Laemmli [29] in a buffer containing 0.2% SDS using 4% (w/v) stacking gels and 10% separating gels [30,31], in a Hoefer Mighty Small mini-electrophoresis system. Samples were prepared in reducing gel loading buffer containing 2% SDS, 10% glycerol, 0.01% bromophenol blue and 5% mercaptoethanol and boiled for 2 min prior to loading. After electrophoresis gels were stained for carbohydrate with PAS [32] and for protein with Coomassie Brilliant Blue G-250.

**Western blotting**

After gel electrophoresis mucins were transferred to a nitrocellulose membrane (Nitrocellulose, 0.22 Micron) using a semi-dry electroblotting unit at 0.8 mA/cm². The transfer buffer used contained 192 mM glycine, 25 mM Tris, 1.3 mM SDS and 20% (v/v) methanol. After electrophoresis non-specific binding was blocked by incubating the membranes overnight in 5% (m/v) low fat milk powder in TBST. The membranes were washed for 3 × 5 min with TBST and incubated for 1 h with HRPO linked secondary antibodies (goat anti-rabbit and rabbit anti-goat) diluted in TBS, 0.05% Tween-20 (TBST) at 4 °C. The membranes were then washed with TBST for 3 × 5 min and incubated for 2 h with rabbit anti-MUC5B and goat anti-MUC7 polyclonal antibodies diluted in 5% (m/v) low fat milk powder in TBST at 1:500 and 1:100 dilutions respectively. The membranes were washed for 3 × 5 min with TBST and incubated for 1 h with HRPO linked secondary antibodies (goat anti-rabbit and rabbit anti-goat) diluted in 5% (m/v) low fat milk powder in TBST at 1:5000 dilution. After another TBST wash (3 × 5 min) bands that interacted with the antibodies were detected by exposing the membrane to ECL detection.

**Amino acid analysis**

The amino acid contents of purified MUC5B and MUC7 mucins were analysed using high pressure liquid chromatography (HPLC) system. The analysis procedure was similar to that of Klapper [33] and Cohen and Strydom [34]. The samples were vacuum-dried and placed in a hydrolysis vessel containing some constant boiling HCl and 1% (v/v) phenol. The vessel was cleaned with nitrogen gas and sealed under vacuum. The samples were then hydrolysed in the gas phase at 110 °C for 24 h. Following hydrolysis, the vials were cooled and vacuum dried to remove the residual HCl. The dried samples were re-dissolved in citrate buffer pH 2.2 and injected into a HPLC column from Waters Associates, Medford, MA., packed with a cation exchange resin (sulfonated polystyrene cross-linked with divinylbenzene) and eluted with a series of buffers ranging from a low (0.25 M trisodium citrate, pH 3.05) to high (0.25 M sodium nitrate, pH 9.5) pH. Detection was carried out using post column derivatization with o-phthalaldehyde (OPA), a fluorescent reagent that reacts with all the amino acids except proline. The relative ratios of the individual amino acids for each sample was determined and compared to each other. For proline detection samples were treated with sodium hypochlorite prior to post column derivatization with o-phthalaldehyde (OPA).

**Toxicity assay**

The toxicity of crude saliva and purified salivary MUC5B and MUC7 mucins to the CD4⁺ CEM SS cells was determined by a toxicity assay. Briefly, 500 μl of the CD4⁺ CEM SS cells in RPMI complete containing 10% Fetal Calf Serum, 1% Penicillin/Streptomycin antibiotic, 10 μmol Fungin and 50 μmol 2-mercaptopoethanol (final concentration 2.5 × 10⁵ cells/ml) was incubated with 250 μl of IL-2 and 250 μl (0.9 mg) of crude saliva or purified salivary MUC5B and MUC7 mucins in a CO₂ incubator for 24 h. As controls CEM SS cells with IL-2 only and IL-2 without CEM SS cells (blank) were used. After spinning at 1400rpm for 5 min, cells were re-suspended in 500 μl of RPMI and live and dead cells were counted using Trypan blue exclusion criteria. The percentage of viable cells was calculated as live cells/total cells × 100.

**Inhibition assay**

The anti-HIV-1 activities of crude saliva and purified salivary MUC5B and MUC7 mucins were tested in an inhibition assay according to the method of Nagashunmugam et al. [3]. Briefly, the crude saliva and purified salivary MUC5B and MUC7 mucins were dissolved in 0.25% PBS and (500 μl or 0.9 mg each) were mixed with 4 ml of the subtype D HIV-1 supernatant fluid (SNF) and incubated for 60 min at 37 °C. As controls heat inactivated HIV-1 and HIV-1 plus media (RPMI 1640 with 10% fetal calf serum and IL-2) were used. The virus was first isolated from an AIDS patient by the Department of Medical Virology, Tygerberg Hospital, University of Stellenbosch, in February 1986, and it was fully characterised and sequenced subsequently. At the end of the incubation period the mixtures (virus plus mucins) and the control (virus plus media) were filtered through 0.45 μm pore size cellulose acetate filter (25 mm diameter), and both the
unfiltered and filtered samples were incubated with CD4⁺
CEM SS cells at 37°C at a concentration of 0.5 × 10⁶ cells/
ml for 30 min, 1 h and 3 h. Cells were then washed three
times with PBS to remove free virus and cultured. Supernatant
fluid was harvested on Day 4 and viral replication
was measured by a qualitative p24 antigen assay. End-
points were calculated by the Reed-Muench formula and
the 50% tissue culture infective dose (TCID₅₀) was
expressed as the highest dilution that produced a positive
qualitative p24 antigen result. All samples were done in
duplicate and the anti-HIV-1 activity of each mucin was
tested in a serial tenfold dilution (10⁻¹ to 10⁻⁴).

Results

Sepharose CL-4B gel filtration

Sepharose CL-4B gel filtration demonstrated that saliva
contains two species of carbohydrate-rich mucin macromolecules
which are distinguishable according to their size. Of these two populations, the glycoprotein (MG1)
was excluded in the void volume (Vₒ) [23] and the glyco-
protein (MG2) in the included volume (Vᵢ) of the gel fil-
tration column [23] (Fig. 1). A sharp PAS positive peak
was seen eluting in the void volume and a broader peak in
the included volume of the column, which was alongside
a protein positive peak. The protein peak that eluted in the
void volume, coinciding with the PAS positive peak, was
much smaller.

SDS-PAGE

To check the purity of the materials eluted in the Vₒ and
the Vᵢ of the gel filtration column, fractions eluting under
these peaks were pooled separately, dialysed extensively
against distilled water, freeze-dried and subjected to 10%
SDS-PAGE and stained with protein Coomassie Bril-
liant Blue G-250 (Fig. 2a and 3a) and for carbohydrate
with PAS (Fig. 2b and 3b).

The PAS positive void volume material gave a strong band
sitting on the top of the stacking and running gels, very
characteristic of the electrophoretic behaviour of large-
sized mucins (Fig. 2b) [30]. On the other hand the material
that eluted in the Vᵢ showed a prominent band of
greater electrophoretic mobility and of relatively smaller
size than Vₒ mucin, in that the mucins slightly entered the
running gel (Fig. 3b). Also there were a range of fainter
bands ranging in size from 66–30kDa (Fig. 3b, lanes 1–3
and 5 and 6). More contaminant protein associated with
mucin was present in the Vᵢ peak (Fig. 3a) than the Vₒ peak
(Fig. 2a) suggesting the need for further purification of the
material that eluted in the included volume of the column.

Mucin purification

Material that eluted in the included volume of the gel fil-
tration column was subjected to density-gradient ultra-
centrifugation in caesium chloride. Mucin rich fractions
from the first density gradient (Fig. 4a) were pooled and
subjected to a second spin in caesium chloride (Fig. 4b),
after which the mucin rich fractions were pooled, dialysed
against distilled water and freeze-dried. SDS-PAGE anal-
ysis of these mucins showed less protein contaminant (Fig.
5, lane 2), except for low molecular weight material
of 30kDa and under. As indicated by the arrows, the PAS
stain of the same material gave two prominent bands
in the region of 220kDa and 46–60kDa (Fig. 5, lane 3).
Traces of material were also seen at 21.5kDa and under
(Fig. 5, lane 3).

Western blotting

To determine the identity of the Vₒ and Vᵢ mucins from the
gel filtration column material eluting under these peaks
was subjected to 10% SDS-PAGE and then transferred to
nitrocellulose membrane and probed with rabbit anti-
MUC5B and goat anti-MUC7 polyclonal antibodies
respectively. The results showed that the Vₒ material sit-
ting on the top of the gel is MUC5B (Fig. 6a, lanes 2 and
3) and the two bands slightly entered the running gel that
interacts with the anti-MUC7 polyclonal antibody are the
two glycoforms of MUC7 (Fig. 6b, lane 3). The two glyco-
forms of MUC7 in Figure 6b are indicated by arrows.

Amino acid analysis

Following the amino acid analysis (Table 1) both MUC5B
and MUC7 mucins were found to contain higher amounts
of threonine, serine, glutamic acid, glycine and aspartic
acid. However, the amount of threonine in MUC7 is very
low. Of these signature amino acids of mucins, serine,
threonine, and proline were found to comprise 26% and
28% of the MUC5B and MUC7 mucins respectively.

Toxicity assay

Prior to the HIV inhibition assay the toxicity of the crude
saliva and purified salivary MUC5B and MUC7 mucins to
the CD4⁺ CEM SS cells was determined by toxicity assay.
Based on this assay (data not shown) no cell death or tox-
icity of these mucins to the CD4⁺ CEM SS cells was
detected.

Inhibition assay

Subsequent to the toxicity assay the anti-HIV-1 activities
of the crude saliva and purified salivary MUC5B and
MUC7 mucins were determined by HIV inhibition assay.
The result revealed that after a 30 min incubation period
during which the mixtures three separate mixtures (HIV-1
plus crude saliva), (HIV-1 plus MUC5B) and (HIV-1 plus
MUC7) were incubated with the CD4⁺ CEM SS cells, no
HIV-1 infection of these cells was observed (Fig. 7). Simult-
naneously, to determine the effect of the incubation
period between the CD4⁺ CEM SS cells and the mixtures
described above on the infectivity of these cells, incuba-
Figure 1
Sepharose CL-4B gel filtration of crude saliva. An aliquot (20 ml) of soluble human crude saliva extracted in 6 M GuHCl containing 10 mM EDTA, 5 mM NEM, 1 mM PMSF and 0.1% CHAPS pH 6.5 was chromatographed and eluted with 4 M GuHCl containing 10 mM EDTA, 5 mM NEM and 0.05% CHAPS pH 6.5 at flow rate of 48 ml/h at room temperature. Fractions were analysed for carbohydrate with PAS at 555 nm (●) and for protein A280 (■). Materials eluted in the void volume (V_o) and included volume (V_i) were pooled separately, dialysed against three changes of distilled water for overnight at 4°C and freeze-dried.

Figure 2
SDS-PAGE analysis of the salivary mucus eluted in the V_o of the Sepharose CL-4B gel filtration column. Freeze-dried material (30 μg) of the V_o prepared in reducing gel loading buffer was separated by 10% SDS-PAGE and stained with Coomassie Brilliant Blue G-250 (a) and PAS (b). The molecular weight marker is indicated by Mw and lanes 1 to 6 represents samples from 6 donors.
Caesium chloride isopycnic density-gradient ultra-centrifugation of the material eluted in the Vi of the gel filtration column. Freeze-dried material (30 μg) of the Vi, prepared in reducing gel loading buffer was separated by 10% SDS-PAGE and stained with Coomassie Brilliant Blue G-250 (a) and PAS (b). The molecular weight marker is indicated by Mw and lanes 1 to 6 represents samples from 6 donors.

Figure 3
SDS-PAGE analysis of the salivary mucus eluted in the Vi of the Sepharose CL-4B gel filtration column. Freeze-dried material eluted in the Vi was dissolved in 4 M GuHCl containing 10 mM EDTA, 5 mM NEM and 0.05% CHAPS pH 6.5 and adjusted to a density of 1.39 to 1.40 g/ml with caesium chloride. Density gradient centrifugation was performed in a Beckman L45 ultra-centrifuge for 48 h at 105 000 g at 4°C. Fractions with high PAS (●) and low protein (Lowry) (■) (a) were pooled and adjust to a density of 1.39 to 1.40 g/ml with caesium chloride for a second step centrifugation (b). Mucin rich fractions with a density (▲) between 1.37–1.42 were pooled, dialysed against three changes of distilled water for overnight at 4°C and freeze-dried.

Figure 4
Caesium chloride isopycnic density-gradient ultra-centrifugation of the material eluted in the Vi of the gel filtration column. Freeze-dried material eluted in the Vi was dissolved in 4 M GuHCl containing 10 mM EDTA, 5 mM NEM and 0.05% CHAPS pH 6.5 and adjusted to a density of 1.39 to 1.40 g/ml with caesium chloride. Density gradient centrifugation was performed in a Beckman L45 ultra-centrifuge for 48 h at 105 000 g at 4°C. Fractions with high PAS (●) and low protein (Lowry) (■) (a) were pooled and adjust to a density of 1.39 to 1.40 g/ml with caesium chloride for a second step centrifugation (b). Mucin rich fractions with a density (▲) between 1.37–1.42 were pooled, dialysed against three changes of distilled water for overnight at 4°C and freeze-dried.
tion was carried out at different time-points (1 h and 3 h). No difference in the rate of inhibition due to time differences was detected (Fig. 7). Serial tenfold dilution (10^{-1} to 10^{-4}) of the mucins was also done to determine the anti-HIV-1 activity of these mucins at the highest dilution. All the mucins showed anti-HIV-1 activity down to the concentration of 0.09 \mu g or in the range of 900 \mu g to 0.09 \mu g (data not shown).

In the controls, where the virus was incubated with the media only, prior to addition to the CD4+ CEM SS cells at all time points (30 min, 1 h and 3 h), 100% of HIV-1 replication or infection of the CD4+ CEM SS cells was detected with the filtrate of the control (HIV-1 plus media) (Fig. 8), no HIV-1 replication or infection of the CD4+ CEM SS cells was detected when the filtrates from the three mixtures were used (Fig. 8).

**Discussion**

In the present study human crude saliva was separated by Sepharose CL-4B gel filtration column into material eluting as two major PAS positive peaks in the void (MG1) and included (MG2) volumes respectively and the material under each peak identified as MUC5B and MUC7 respectively, confirming previous findings of Thornton et al. [23]. Amino acid analysis further supported this material to be mucin [35]. The small protein peak that eluted in the void volume of the gel filtration column, under the large excluded PAS positive peak is very likely the protein moiety of MUC5B (Fig. 1) [31]. The elution of the larger protein peak, which begins under the included volume (Vi) PAS positive peak and elutes nearer the total volume of the column suggests that gel filtration was partially but not entirely successful in removing a considerable amount of protein contaminant from the crude saliva. SDS-PAGE analysis of the PAS positive Vi peak material, when stained for protein with Coomassie Blue, still showed protein contamination of MUC7 (Fig. 2c). This material was therefore further purified by caesium chloride density gradient ultra-centrifugation.

To avoid any possible endogenous enzymatic degradation, sample analysis was carried out in 6 M GuHCl containing protease inhibitors such as EDTA, NEM, and PMSF. According to the report by Carlstedt et al. [36] while PMSF and EDTA inhibit serine and metallo-proteases respectively, NEM which inhibits thiol proteases is reported to reduce disulfide bond formation between mucins and non-mucinous components of the saliva by blocking the free thiol groups on mucins.

Salivary mucins are known to bind with the non-mucinous components of the saliva such as amylase, lysozyme, proline-rich proteins, statherin, histatins, SIgA and lactoferrin which may change their physicochemical properties [37-39]. As reported by Mehrotra et al. [40] and Zalewska et al. [41] the hydrophobic regions of mucins are responsible for these complex formations as well as for their sticky characters. As a result mucins may stick to gels and dialysis tubes during the purification and dialysis processes. Therefore in the present study CHAPS a detergent was included in the chromatography buffer to minimize the sticky characteristic and prevent loss of mucins during dialysis and column chromatography [42].
The electrophoretic behaviour of the purified saliva was typical of mucins which, because of their large size, appear at the top of the stacking and running gels (Fig. 2b and 3b, and Fig 5, lane 3) [31,43,44]. The MUC7 mucin showed two bands on SDS-PAGE (Fig 5, lane 3) and Western Blotting (Fig. 6b, lane 3). This result agreed with that of Reddy et al. [45], Mehrotra et al. [40] and Bolscher et al. [42], which revealed the presence of two isoforms of MUC7, designated MUC7a and MUC7b in saliva. According to these authors, the two isoforms have an identical amino acid composition but a different glycosylation pattern with respect to sialic acid and fucose. In the case of MUC5B, although SDS-PAGE analysis revealed the presence of two closely situated mucin bands on the top of the gel (Fig. 2b), Western blotting gave just one band (Fig. 6a, lanes 2 and 3), again at the top of the membrane.

The amino acid analysis has shown the presence of higher amounts of threonine, serine, glycine, glutamic acid, and aspartic acid in salivary MUC5B and MUC7 mucins. This agreed with the findings of Tabak et al. [46] that, mucins contain large amounts of serine, threonine, proline,
glutamic acid, glycine and alanine. The presence of methionine in a very small amount also agreed with that of Thomsson et al. [47]. Strangely enough threonine presented in smaller amount than the expected value especially in MUC7. According to Mehrotra et al. [40], this could be due to the level of oligosaccharide substitution of this residue.

It has been shown that the incubation of HIV with human whole and submandibular saliva leads to a decrease in viral infectivity and that this inhibition is considerably reduced upon filtration of the saliva [11,15,18]. These observations suggest that saliva-induced viral aggregation serves to clear the virus from the oral cavity and lessen the possibility of oral transmission [11]. It has also been suggested that the most likely candidate in the oral defence against AIDS is a macromolecular component [9], specifically the mucus component of oral secretions [2]. Although these researchers speculated that crude saliva [8], MUC5B and MUC7 [2], two of the known mucins in saliva [23] are potentially involved in inhibition through the entrapment of virus particles, a definitive attempt to purify, identify and individually test these purified mucins from saliva, against the AIDS virus, has not been done.

Although the HIV-1 Subtype C virus is currently the most prevalent in South Africa, the Subtype D which was used in this study was found during the early HIV epidemic in South Africa and is still prevalent in the country, although less frequently. Although we would very much have liked to use the Subtype C strain, unfortunately, the Subtype D is the only laboratory adapted strain available for an in vitro HIV assay, in the entire country. As described in the methods, this virus was first isolated from an AIDS patient.

### Table 1: Amino acid composition of MUC5B and MUC7 mucins.

| Amino acids | MUC5B (mole %) | MUC7 (mole %) |
|-------------|----------------|---------------|
| Aspartic acid | 8.9            | 9.1           |
| Threonine   | 10.0           | 4.0           |
| Serine      | 7.4            | 5.5           |
| Glutamic acid | 9.0           | 12.4          |
| Proline     | 8.5            | 18.6          |
| Glycine     | 9.0            | 14.4          |
| Alanine     | 6.6            | 3.9           |
| Valine      | 6.4            | 4.2           |
| Methionine  | 1.6            | 1.7           |
| Isoleucine  | 4.0            | 2.9           |
| Leucine     | 7.6            | 4.7           |
| Tyrosine    | 3.2            | 1.7           |
| Phenylalanine | 3.8           | 1.9           |
| Lysine      | 4.6            | 4.7           |
| Histidine   | 4.4            | 3.9           |
| Arginine    | 4.0            | 5.6           |

**Figure 7**

Inhibition of HIV-1 activity by human crude saliva and purified salivary MUC5B and MUC7 mucins. Crude saliva and purified salivary MUC5B and MUC7 mucins (0.9 mg each) were incubated with subtype D HIV-1 for 60 min and filtered through 0.45 μm pore size cellulose acetate filter. As controls HIV-1 treated with media and heat inactivated HIV-1 were used. The unfiltered samples were then incubated with CD4+ CEM SS cells at a concentration of 0.5 × 10⁶ cells/ml for 30 min, 1 h and 3 h. After PBS wash cells were cultured and viral replication was measured by a qualitative p24 antigen assay.
by the Department of Medical Virology, Tygerberg Hospital (Cape Town, South Africa) in February 1986, and fully characterised and sequenced subsequently. Simultaneously the T cell lines, CEM-SS cells which were used in this experiment are known to produce distinct and repeatable syncytia formation when infected with HIV-1. As reported by Nara et al. [48], following the addition of HIV-1, these cells develop easily quantifiable syncytia formation in four to six days.

In this study we have demonstrated that when the HIV-1 was incubated with the crude saliva and purified salivary MUC5B and MUC7 mucins (0.9 mg each) and subsequently added to the CD4+ CEM SS cells no viral replication or infection of the CEM SS cells was detected by the p24 antigen assay. However, when the HIV-1 was incubated with media instead (as control), 100% infection of the CD4+ CEM SS cells was detected. A possible explanation of the findings of this study is that when mucins are incubated with HIV, the mucins trap or aggregate the virus, leaving it entangled in the mucin mesh which is retarded by filtration through a 0.45 μm pore cellulose acetate filter [3,8,17,20,21], thus preventing the virus from entering the host cells.

To prove this hypothesis we filtered the mixtures (HIV-1 plus crude saliva), (HIV-1 plus MUC5B), (HIV-1 plus MUC7) and the control (HIV-1 plus media), at the end of the incubation period, through a 0.45 μm pore size cellulose acetate filter, and added the filtrates to the CD4+ CEM SS cells. The filtrates from each of the mixtures failed to infect the CD4+ CEM SS cells, as shown by the absence of measurable p24 activity. This suggested that the mucins aggregated all the viruses, hence leaving no free viruses in the filtrates to cause viral infection. However, the filtrates from the control (HIV-1 plus media) where mucins are absent, gave 100% HIV-1 replication or infection of the CEM SS cells. Therefore the media, unlike the mucins failed to aggregate the viruses, resulting in free viruses in the filtrate, which were then infective to the CD4+ CEM SS cells.

Although the inhibition of HIV-1 by mucins is thought to be by aggregation of the virus prior to host cell entry [3,8,11,18], the specificity of this aggregation is not at all clear. The findings by Fox et al. [9] and Nagashunmugam et al. [3], which demonstrated low or no potency of saliva against herpes simplex virus (HSV), HIV-2, simian immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, hepatitis B virus and adenovirus implies that the specific aggregation of HIV-1 by saliva or purified mucins could require some specificity. One other possibility is that the negative charges on mucins through sialic acid and sulphate groups [35] could be responsible for specific interactions with receptors on the virus.

![Figure 8](image-url)

**Figure 8**

Inhibition of HIV-1 activity by human crude saliva and purified salivary MUC5B and MUC7 mucins. Crude saliva and purified salivary MUC5B and MUC7 mucins (0.9 mg each) were incubated with subtype D HIV-1 for 60 min and filtered through 0.45 μm pore size cellulose acetate filter. As controls HIV-1 treated with media and heat inactivated HIV-1 were used. The filtrates of the mixtures were then incubated with CD4+ CEM SS cells at a concentration of 0.5 × 10⁶ cells/ml for 30 min, 1 h and 3 h. After PBS wash cells were cultured and viral replication was measured by a qualitative p24 antigen assay.
This study has shown that mucins and mucins have protective properties against the HIV virus in certain situations. More light needs to be shed on these processes to understand further the role of mucins against infection to be able to design further studies that will investigate the significance of mucins in HIV-AIDS.

**Authors’ contributions**

HH carried out the biochemical studies and drafted the manuscript. AM conceived of the study, participated in its design and coordination and finalised the manuscript. CDdB established and carried out the HIV inhibition assay. ZL participated in the biochemical studies. DK contributed ideas to the design and coordination of the study. All authors read and approved the final manuscript.

**Acknowledgements**

We thank Dr Jerry Rodrigues for the amino acid analysis and the University of Cape Town Postgraduate Funding Office for financial support. This work was supported by the South African Medical Research Council grant of Cape Town Postgraduate Funding Office for financial support. This work was supported by the South African Medical Research Council grant CHM504-415566.

**References**

1. Fultz PN: Components of saliva inactivate human immunodeficiency virus. Lancet 1986, 2:1215.

2. Bilscher JGM, Nazim K, Ran L, Van Engelenburg FAC, Schuitemaker H, Veerman ECI, Nieuw Amerongen AV: Inhibition of HIV IIIB and clinical isolates by human parotid, submandibular, sublingual and palateine saliva. *Eur J Oral Sci* 2002, 110:149-156.

3. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein L, Malamud D: Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997, 13:371-376.

4. Phillips J, Qureshi N, Barr C, Menrard DR: Low level of cell-free HIV detected at high frequency in saliva from HIV-1 infected individuals. *AIDS* 1994, 8:1011-1012.

5. Wahl SM, Worley JA, Jin W, McNeely TB, Eisenberg S, Fasching C, Davis C, Abrams WR: Endogenous inhibitors of human immunodeficiency virus. Arch Oral Biol 1993, 38:150-153.

6. Yeh CK, Fox PC, Goto Y, Austin HA, Brahim JS, Fox CH: Human immunodeficiency virus (HIV) and HIV infected cells in saliva and salivary glands of a patient with systemic lupus erythematosus. *J Rheumatol* 1992, 19:1810-1812.

7. Baron S, Poast J, Cloyd MW: Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. *Arch Intern Med* 1999, 159:303-310.

8. Bergey EJ, Cho PI, Blumberg BM, Hammarstedt ML, Rekosh D, Epstein LG, Levine MJ: Interaction of HIV-1 and human salivary mucins. *J Acquir Immune Defic Syndr* 1994, 7:995-1002.

9. Fox PC, Woff LF, Yeh CK, Atkinson JC, Baum BJ: Saliva inhibits HIV-1 infectivity. *J Am Dent Assoc* 1988, 116:635-637.

10. Goto Y, Yeh CK, Notkins AL, Prabhakar BS: Detection of proviral sequence in saliva of patients infected with human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* 1991, 7:343-347.

11. Malamud D, Davis C, Berthold P, Roth E, Friedman H: Human submandibular saliva aggravates HIV. *AIDS Res Hum Retroviruses* 1993, 9:633-637.

12. Qureshi NM, Barr CE, Seshamma T, Reidy J, Pomerantz RJ, Bagasra O: Infection of oral mucosal cells by human immunodeficiency virus type 1 in seropositive persons. *J Infect Dis* 1995, 171:190-193.

13. Yeh CK, Handelman B, Fox PC, Baum BJ: Further studies of salivary inhibition of HIV-1 infectivity. *J Acquir Immune Defic Syndr* 1992, 5:898-903.

14. Yeung SCH, Kazazi F, Randle CGM, Howard RC, Rizvi N, Downie JC, Donovan BJ, Cooper DA, Sekine H, Dwyer DE, Cunningham AL: Patients infected with human immunodeficiency virus type I have low levels of virus in saliva even in the presence of periodontal disease. *J Infect Dis* 1993, 167:803-809.

15. Keeney S, Davis C, Abrams WR, Billington PC, Nagashunmugam T, Friedman H, Malamud D: Submandibular salivary proteases: lack of a role in anti-HIV activity. *J Dent Res* 1998, 77:1515-1519.

16. Moore BE, Faitz CM, Coppenhaver DH, Mark Nichols C, Kalmaz GD, David Bessman J, Cloyd MW, Lynch DP, Prabhakar BS, Baron S: HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. *J Am Dent Assoc* 1993, 124:67-74.

17. Archibald DW, Cole GA: In vitro inhibition of HIV-1 infectivity by human salivas. *AIDS Res Hum Retroviruses* 1990, 6:1425-1432.

18. Malamud D, Nagashunmugam T, Davis C, Kennedy S, Abrams WR, Kream R, Friedman HM: Inhibition of HIV infectivity by human saliva. *Oral Dis* 1997:58-63.

19. Wu Z, Van Ryk D, Davis C, Abrams WR, Chalken I, Magnani J, Malamud D: Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. *AIDS Res Hum Retroviruses* 2003, 19:201-209.

20. Shugars DC, Alexander AL, Fu K, Friel SA: Endogenous salivary inhibitors of human immunodeficiency virus. *Arch Oral Biol* 1999, 44:445-453.

21. Shugars DC, Wahl SM: The role of the oral environment in HIV-1 transmission. *J Am Dent Assoc* 1998, 129:851-858.

22. Rose MC, Voonow JA: Respiratory tract mucin genes and mucin glycoproteins in healthy and disease. *Physiol Rev* 2006, 86:245-278.

23. Thornton DJ, Khan N, Mehrrota R, Howard M, Veerman E, Packer NH, Sheehan JK: Salivary mucin MG1 is comprised almost entirely of different glycosylated forms of the MUC5B gene product. *Glycobiology* 1999, 9:293-302.

24. Chen Y, Zhao YH, Kalasalavti TB, Hamati E, Nehrke K, Le AD, Ann DK, Wu R: Genome-wide screening and identification of a novel gel-forming mucin MUC19/Muc19 in glandular tissues. *Am J Respir Cell Mol Biol* 2004, 30:155-165.

25. Shugars DC, Wahl SM, Wu R: The role of saliva in the inactivation of HIV-1. *AIDS* 2005, 19:171-181.

26. Creeth JM, Denborough MA: The use of equilibrium-densitogradient methods for the preparation and characterization of blood-group-specific glycoproteins. *Biochem J* 1970, 117:879-91.

27. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970, 227:680-685.
37. Ge J, Catt DM, Gregory RL: Streptococcus mutants surface α-enolase binds salivary mucin MG2 and human plasminogen. *Infect Immun* 2004, 72:6748-6752.

38. Situ H, Bobek LA: In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain I. *Antimicrob Agents Chemother* 2000, 44:1485-1493.

39. Tabak LA: In defence of the oral cavity: structure, biosynthesis, and function of salivary mucins. *Annu Rev Physiol* 1995, 57:547-64.

40. Mehrotra R, Thornton DJ, Sheehan JK: Isolation and physical characterization of the MUC7 (MG2) mucin from saliva: evidence for self-association. *Biochem J* 1998, 334:415-422.

41. Zalewska A, Zwierz K, Żółkiewski K, Gindzienski A: Structure and biosynthesis of human salivary mucins. *Acta Biochim Pol* 2000, 47:1067-1079.

42. Bolscher JG, Groenink J, van der Kwaak JS, van den Keijbus PAM, van’t Hof W, Veerman EC, Nieuw Amerongen AV: Detection and quantification of MUC7 in submandibular, sublingual, palatine, and labial saliva by anti-peptide antiserum. *J Dent Res* 1999, 78:1362-1369.

43. Mall AS, Merrifield E, Fourie J, McLeod HA, Hickman R: Alterations in porcine gastric mucin during the development of experimental ulceration. *Digestion* 1997, 58:138-146.

44. Pearson JP, Allen A, Parry S: A 70 000-molecular-weight protein isolated from purified pig gastric mucus glycoprotein by reduction of disulphide bridges and its implication in the polymorphic structure. *Biochem J* 1981, 197:153-162.

45. Reddy MS, Bobek LA, Haraszthy GG, Biesbrock AR, Levine MJ: Structural features of the low-molecular-mass human salivary mucin. *Biochem J* 1992, 287:639-643.

46. Tabak LA, Levine MJ, Mandel ID, Ellison SA: Role of salivary mucins in the protection of the oral cavity. *J Oral Pathol* 1982, 11:1-17.

47. Thomson KA, Prakophsol A, Leffler H, Reddy MS, Levine MJ, Fisher SJ, Hansson GC: The salivary mucin MG1 (MUC5B) carries a repertoire of unique oligosaccharides that is large and diverse. *Glycobiology* 2002, 12:1-14.

48. Nara PL, Hatch WC, Dunlop NM, Robey WG, Arthur LO, Gonda MA, Fischinger PJ: Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. *AIDS Res Hum Retroviruses* 1987, 3:283-302.